A review: Brain specific delivery

Deepti R. Damle; Dr. Archana D. Kajale; Dr. Madhuri A. Channawar; Dr. Shilpa R. Gawande

doi:10.30574/gscbps.2020.13.2.0349

Authors

Deepti R. Damle Department of Pharmaceutics P. Wadhwani College of Pharmacy, Yavatmal, (M.S). 445001, India
Dr. Archana D. Kajale Department of Pharmaceutics P. Wadhwani College of Pharmacy, Yavatmal, (M.S). 445001, India
Dr. Madhuri A. Channawar Department of Pharmaceutics P. Wadhwani College of Pharmacy, Yavatmal, (M.S). 445001, India
Dr. Shilpa R. Gawande Department of Pharmaceutics P. Wadhwani College of Pharmacy, Yavatmal, (M.S). 445001, India

DOI:

https://doi.org/10.30574/gscbps.2020.13.2.0349

Keywords:

Brain targeting, BBB, Nanoparticles, Recent advancement, Liposomes

Abstract

The overall prevalence rate for CNS pathology has demonstrated that approximately more than one billion people are undergoing from disorders of central nervous system. The most distressing fact about delivery of drugs to the CNS is the presence of blood brain barrier that have a tendency to impair the drug distribution and denotes the major impediment for the development of CNS drugs. Neuropeptides and many drugs which are hydrophilic in nature possibly will encompass the intricacy while passing the blood brain barrier. The net amount of delivered drug (medicinal agent) and its capability to gain access to the pertinent target sites are the main considering points for CNS drug development. Brain targeted drug delivery to the brain is valuable in the diseases of brain. (Alzheimer’s diseases, meningitis, brain abscess, epilepsy, multiple sclerosis, neuromylitis optica, sleeping disorders etc). Whereby high concentration can be gained with lesser side effects that occur because of release of drugs. The simplest method of targeting to brain is to obtain a therapeutic. Brain targeting systems to remain in the brain region by crossing BBB and hence significantly helps in increasing therapeutic activity. There is an increasing attraction towards brain targeting and sue to its immense application in the treatment of various CNS diseases because mostly drugs are unable to cross the BBB. This review article discuss one of the novel technology “nanotechnology” and other aspects that has been developed to target the brain and possess various clinical benefits such as reduced drug dose, less side effects, non-invasive routed, and better patient compliance.

Metrics

Metrics Loading ...

References

A Misra, C Ganesh, Shahiwala, SP Shah.Drug delivery to current nervous system: a review J Pharm Pharm Sci. 2003; 6: 252-73.

AH Schinkel, E Wagennar, C Mol, L van Deemter.P-glycoprotein in the blood brain barrier of mice influences the brain penetration and pharmacological activity of many drugs Journal of Clinical Investigation. 1996; 97: 2517.

WM Pardridge.Blood-brain barrier drug targeting: the future of brain drug development Molecular interventions. 2003; 3: 90.

W Loscher, H Potschka.Blood-brain barrier active efflux transporters: ATP binding cassette gene family NeuroRx. 2005; 2: 86-98.

MA Moses, H Brem, R Langer.Advancing the field of drug delivery: taking aim at cancer Cancer cell. 2003; 4: 337-341.

MI Alam, S Beg, A Samad, S Baboota, K Kohli, J Ali, M Akbar, Strategy for effective brain drug delivery European journal of pharmaceutical sciences. 2010; 40: 385-403.

DR Groothuis.The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery Neuro-oncology. 2000; 2: 45-59.

Tsuji A. Small molecular drug transfer across the blood–brain barrier via carrier-mediated transport systems. NeuroRx. 2005; 2:54–62.

R Singh JW Lillard.Nanoparticle-based targeted drug delivery Experimental and molecular pathology. 2009; 86: 215-223.

S Acharya, SK Sahoo.PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effec Advanced drug delivery reviews. 2011; 63: 170-183.

JM Koziara, PR Lockman, DD Allen, RJ Mumper In situ blood–brain barrier transport of nanoparticles Pharmaceutical research. 2003; 20: 1772-1778.

A Kumari, SK Yadav, SC Yadav. Biodegradable polymeric nanoparticles based drug delivery systems Colloids and Surfaces B: Biointerfaces.2010; 75: 1-18.

KA Janes, MP Fresneau, A Marazuela, A Fabra, MAJ Alonso. Chitosan nanoparticles as delivery systems for doxorubicin Journal of controlled Release. 2001; 73: 255-267.

T Neuberger, B Schöpf, H Hofmann, M Hofmann, B. Von Rechenberg.Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system Journal of Magnetism and Magnetic Materials. 2005; 293:483-496.

MF Heyderman, RS Michael BD et al. The UK joint specialist socities guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. J Infect. 2016; 72:405-38.

D Muzumdar Central nervous system infections and the neurosurgeon: A perspective. Int J Surg. 2011; 9:113-6.

A Paoli, M Canato, L Toniolo, AM Bargossi, M Neri, M Mediati, D Alesso, G Sanna, KA Grimaldi, AL Fazzari, A Bianco. The ketogenetic diet: an underappreciated therapeutic option? La Clinican Terapeutica. 2011,2009;162, e-145-e153.

MM Abdel Fatah, SY Alokbi, Ramadan, SKholoud, DA Mohamed, SE Mohammed. 2009.

Jarius S, Wildemann B. The history of neuromylitis optica. J Neuroinflammation. 2013; 10:8.

Understanding Sleep: Brain Basics. Office of Communications and Public Liaison, National Institute of Neurological Disorders and Stroke, Bethesd, Md.

E Bossy-Wetzel, R Schwarzenbacher, SA Lipton. Molecular pathways to neurodegeneration, Nature Medicine. 2004; 10: 2-9.

Lingineni K, Belekar V, Tangadpalliwar SR, et al. The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood-brain barrier (BBB) permeability, Mol Divers. 2017; 21:355–65.

Medicinal chemical properties of successful central nervous system drugs. Pajouhesh H, Lenz GRNeuroRx. 2 Oct. 2005; 4:541-53.

Abbott NJ, Patabendige, AA Dolman, DE Yusof, SR Begley DJ.Structure and Function of the blood-brain barrier. Neurobiol Dis. 2009; 37:13-25.

Abbott NJ, Khan EU, Rollinson CM, Reichel A, Janigro D, Dombrowski SM, Dobbie MS, Begley DJ, Drug resistance. BBB breakdown. 2002; 243:38-47.

C Muller–Goymann. Physiochemical characterization of colloidal drug delivery systems such as reverse micelles vesicles liquid crystals and nanoparticles for topical administration.

Tam SJ, Richmond DL, Kaminker JS, Modrusan Z, Martin-McNulty B, Cao TC, Weimer RM, Carano RA, Bruggen N, Watts RJ. Death receptors DR6 and TROY regulate brain vascular development. Dev Cell. 2012; 22:403-17.

Modern Pharmaceutics (Gilbert S.Banker, 4th edition) Targeted drug delivery system, Vyas and Khar Biopharmaceutics and Pharmakokinetics; Bramhankar.

S.C Rastogi, K.Sambulingam (Anatomy and Physiology); Modern Pharmaceutics.

A Minn, S Leclerc, JM Heydel et al.Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrierJournal of Drug Targeting, 2002;10(4): 285r–296r.

M Young, JD Hoheisel, T Efferth.Therapeutic and diagnostic applications of nanoparticles Current Drug Targets. 2011; 12: 357–365.

L Braydich Stolle, S Hussain, JJ Schlager, MC Hoffman. In-vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicological sciences. 2005; 88: 412-419.

FRe, M Gregori, M Masserini. Nanotechnology for neurodegenerative disorders Nanomedicine NBM. 2012; 8(1): S51–S58.

C Pardeshi, P Rajput, V Belgamwar et al.Solid lipid based nanocarriers: an overview Acta Pharmaceutica. 2012; 62(4): 433–472.

KC Petkar, SS Chavhan, S Agatonovik-Kustrin, KK Sawant.Nanostructured materials in drug and gene delivery: a review of the state of the art Critical Reviews in Therapeutic Drug Carrier Systems. 2011; 28(2): 101–164.

X Montet, M Funovics, K Montet-Abou, R Weissleder, L Josephson.Multivalent effects of RGD peptides obtained by nanoparticles display Journal of Medicinal Chemistry. 2006; 49(20):6087–6093.

JM Provenzale GA Silva.Uses of nanoparticles for central nervous system imaging and therapy American Journal of Neuroradiology. 2009; 30(7): 1293–1301.

R Gabathuler.Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiology of Disease. 2010; 37(1): 48–57.

M Budai M Szógyi.Liposomes as drug carrier systems. Preparation, classification and therapeutical advantages of liposomes Acta Pharmaceutica Hungarica. 2001; 71(1): 114–118.

F Lai, AM Fadda, C. Sinico.Liposomes for brain delivery Expert Opinion on Drug Delivery. 2013.

F Artzner, R Zantl, JO Rädler.Lipid-DNA and lipid-polyelectrolyte mesophases: structure and exchange kineticsCellular and Molecular Biology. 2000; 46(5): 967–978.

Nanomedicine. Feb 2015; 11(2):391-400.

K Honjo, SE Black, NP Verhoeff.Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade Canadian Journal of Neurological Sciences. 2012; 39(6): 712–728.

JR Kanwar, B Sriramoju, RK Kanwar.Neurological disorders and therapeutics targeted to surmount the blood-brain barrier International Journal of Nanomedicine. 2012; 7: 3259–3278.

Pehlivan SB. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res. 2013; 30:2499–511.

Statistics adapted from the American Cancer Society's publication, Cancer Facts & Figures , the ACS website, the CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in, and the National Cancer Institute website. 2012-2016, January 2020.

MA Petty EH Lo.Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammationProgress in Neurobiology. 2002; 68(5): 311–323.

Fan W, Wu Y, Li XK, et al. Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen.,Eur J Med Chem. 2011; 46:3651–61.

R Gabathuler.Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiology of Disease. 2010; 37(1): 48–57.

Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016; 15:275–92.

WM Pardridge.Drug transport across the blood-brain barrier Journal of Cerebral Blood Flow & Metabolism. 2012; 32(11):1959–1972.